Form 8-K · Current report
Labcorp 8-K, filed Jul 30, 2026
- Filed
- CIK
- 0000920148
- Accession no.
- 0000920148-26-000162
Summary
Labcorp reported second-quarter 2026 revenue of $3.73 billion, up 5.8% from a year earlier, with diluted EPS of $3.64 and adjusted EPS of $4.99, up 14.9%, and raised its full-year 2026 revenue growth and adjusted EPS guidance. The company also announced a $1.0 billion increase in its share repurchase authorization, bringing the remaining total to $1.4 billion, and said it advanced its oncology offerings and launched the Marker by Labcorp genetic health panel.
Key points
- Second-quarter 2026 revenue was $3.73 billion versus $3.53 billion a year earlier, with organic growth of 4.2%.
- Full-year 2026 guidance was raised to revenue growth of 5.4% to 6.3% and adjusted EPS of $18.10 to $18.55, up 30 cents at the midpoint.
- The company invested $225.7 million in acquisitions, repurchased $353.8 million of stock, paid $58.7 million in dividends, and retired $500.0 million in senior notes during the quarter.
- Labcorp said it launched ColoSense nationwide as the first FDA-approved RNA-based colorectal cancer screening test with at-home collection, and added a DPYD genotyping test.
- The company completed acquisitions of select outreach laboratory services from Parkview Health and of Tribal Diagnostics.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. Item 9.01. Financial Statements and Exhibits. Exhibit Exhibit Name Exhibit 99.1 Press Release dated July 30, 2026 issued by Labcorp titled “Labcorp Announces 2026 Second Quarter Results” Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Exhibit 99.1: EX-99.1 2 form8-kexhibit9912q26.htm EX-99.1 FOR IMMEDIATE RELEASE Contact: Dewey Steadman - Investors Racquel White - Media [email protected] [email protected] Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance •Results from operations for second quarter 2026 versus second quarter 2025: ◦Revenue: $3.73 billion vs. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.